SPL

0.00%

9.7¢ starpharma holdings limited

Broker predictions/Pound of flesh, page-22

First 22 Last

Share
Profile

Follow
jazzapat

587 Posts.

79

27/11/18

18:02

Post #: 36658627
Share

Originally posted by Myownmoney: ↑

Thanks thrasher, I think the areas identified to you from investor relations could fall in both Starpharma's and Aspen's area of responsibility.
If somebody could pin management down to find out how long Starpharma has delayed launch after they had provided updates indicating launch soon and in the near future, I'm sure we would all appreciate it.
Does Starpharma have a production issue causing a shortage in production stock, delaying the launch of Vivagel in Australia?
How can Starpharma management explain why Aspen has not launched Vivagel in preparation of the busiest sales cycle of the year?

Below are just a few examples of the tone used to describe the launch potential, soon, near future and as we know.

Outlook -Aspen’s launch of Vivagel BV as Fleurstat BV gel inAustralia. 25 Jan 2018
“With TGA approval now in hand for Vivagel BV, pharmacistswill soon be selling our product in Australia” 26 Feb 2018
“In Australia, Vivagel BV is licensed to Aspen Pharacare,who will launch the product under the Fleurstat brand in the near future.” 30April 2018
Backpedaling – “Extensive preparations continue for thelaunch of Vivagel BV in a number of regions, including Australia” 17 July 18 “Thisincluded marketing and sales planning, as well as market research by partnersto support launches”
“As launch timing of VivaGel BV in each region is controlledby Starpharma’s partners, optimal launch timings are being scheduled takingaccount of important in-market factors, such as new product/sales cycles in therelevant outlets.” Quarterly Cashflow report 26 Oct 2018.

I hope to just provide my thoughts in the hope somebody may ask a more appropriately worded question at the AGM to cover common concerns that we may share. GLTAH I have subjected you all to enough of my frustrations today.

Expand

The ongoing delay to launch in Australia is becoming concerning. I would like to know specific feedback from pharmacies about listing vivagel e.g. have any pharmacy chains indicated they will list vivagel and conversely have any elected to not stock vivagel during recent range reviews.

i want to know is the delay due to less demand than anticipated or other reasons.

SPL Price at posting: $1.52 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BUX

Buxton projects new graphite province discovery at WA Narryer play

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 17 more messages in this thread...

First 22 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 9.7¢		Change 0.000(0.00%)		Mkt cap ! $40.48M

Open	High	Low	Value	Volume
9.9¢	9.9¢	9.5¢	$35.24K	364.0K

Buyers (Bids)

No.	Vol.	Price($)
3	18326	9.5¢

Sellers (Offers)

Price($)	Vol.	No.
9.8¢	15262	2

View Market Depth

No.	Vol.	Price($)
2	8326	0.095
3	160000	0.094
2	134306	0.092
3	81442	0.090
1	30000	0.089

Price($)	Vol.	No.
0.098	5000	1
0.100	38876	3
0.105	199768	2
0.110	168286	9
0.115	85453	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

SPL (ASX) Chart

Broker predictions/Pound of flesh, page-22

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Broker predictions/Pound of flesh, page-22

Top Stories

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News